{"success":true,"data":{"pressRelease":{"id":"52388","rtpr_id":"nACSh1WNha","ticker":"NVNO","exchange":"NASDAQ","all_tickers":["NVNO"],"title":"enVVeno Medical to Participate in the Virtual Investor Closing Bell Series","author":"ACCESSWIRE","published_at":"2026-06-02T13:01:00.552Z","article_body":"Live video webcast with Robert Berman, Chief Executive Officer of enVVeno\nMedical, on Tuesday, June 9(th)at 4:00 PM ET\n\nRegister here\n(https://us02web.zoom.us/webinar/register/WN_jpAkfamoQHuc2H0QWpVV_A#/registration)\n\nIRVINE, CA / ACCESS Newswire (https://www.accessnewswire.com/) / June 2, 2026\n/ enVVeno Medical Corporation (Nasdaq:NVNO) (\"enVVeno\" or the \"Company\"), a\ncompany setting new standards of care for the treatment of deep venous\ndisease, today announced that Robert Berman, Chief Executive Officer\n(https://pr.report/m51t) of enVVeno Medical will participate in a Virtual\nInvestor Closing Bell (https://pr.report/m51u) event on Tuesday, June 9, 2026\nat 4:00 PM ET.\n\nAs part of the event, Mr. Berman will discuss the Company's recently reported\nIDE approval of its enVVe(®) System, marking a first-ever FDA IDE approval\nfor a U.S. pivotal study of a non-surgical replacement venous valve.\n\nAdditionally, there will be a live question and answer session with audience\nparticipants. Mr. Berman will answer as many questions as possible in the time\nallowed.\n\nA live video webcast (https://pr.report/m51v) will be available on the Events\n(https://pr.report/m51w) page of the Company's website (www.envveno.com). A\nwebcast replay will become available two hours following the live event and\nwill be accessible for 90 days.\n\nAbout enVVeno Medical Corporation\n\nenVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, clinical-stage\nmedical device Company focused on the advancement of innovative bioprosthetic\n(tissue-based) solutions to improve the standard of care for the treatment of\ndeep venous disease. The Company is currently developing the enVVe system,\nwhich includes a first-in-class non-surgical replacement venous valve being\ndeveloped for the treatment of severe Deep Venous Insufficiency (DVI). The\nenVVe valve is designed to act as one-way valve, to help assist in propelling\nblood up the leg, and back to the heart and lungs. As a transcatheter\ndelivered device, the enVVe procedure will be performed under light sedation\nand should not require an over-night hospital stay.\n\nINVESTOR CONTACT:\n\nJTC Team, LLC\nJenene Thomas\nNVNO@jtcir.com\n(908) 824-0775\n\nSOURCE: enVVeno Medical Corporation\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/biotechnology/envveno-medical-to-participate-in-the-virtual-investor-closing-bell-series-1172665)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSh1WNha","title":"enVVeno Medical to Participate in the Virtual Investor Closing Bell Series","author":"ACCESSWIRE","ticker":"NVNO","created":"2026-06-02T13:01:00.552Z","tickers":["NVNO"],"exchange":"NASDAQ","article_body":"Live video webcast with Robert Berman, Chief Executive Officer of enVVeno\nMedical, on Tuesday, June 9(th)at 4:00 PM ET\n\nRegister here\n(https://us02web.zoom.us/webinar/register/WN_jpAkfamoQHuc2H0QWpVV_A#/registration)\n\nIRVINE, CA / ACCESS Newswire (https://www.accessnewswire.com/) / June 2, 2026\n/ enVVeno Medical Corporation (Nasdaq:NVNO) (\"enVVeno\" or the \"Company\"), a\ncompany setting new standards of care for the treatment of deep venous\ndisease, today announced that Robert Berman, Chief Executive Officer\n(https://pr.report/m51t) of enVVeno Medical will participate in a Virtual\nInvestor Closing Bell (https://pr.report/m51u) event on Tuesday, June 9, 2026\nat 4:00 PM ET.\n\nAs part of the event, Mr. Berman will discuss the Company's recently reported\nIDE approval of its enVVe(®) System, marking a first-ever FDA IDE approval\nfor a U.S. pivotal study of a non-surgical replacement venous valve.\n\nAdditionally, there will be a live question and answer session with audience\nparticipants. Mr. Berman will answer as many questions as possible in the time\nallowed.\n\nA live video webcast (https://pr.report/m51v) will be available on the Events\n(https://pr.report/m51w) page of the Company's website (www.envveno.com). A\nwebcast replay will become available two hours following the live event and\nwill be accessible for 90 days.\n\nAbout enVVeno Medical Corporation\n\nenVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, clinical-stage\nmedical device Company focused on the advancement of innovative bioprosthetic\n(tissue-based) solutions to improve the standard of care for the treatment of\ndeep venous disease. The Company is currently developing the enVVe system,\nwhich includes a first-in-class non-surgical replacement venous valve being\ndeveloped for the treatment of severe Deep Venous Insufficiency (DVI). The\nenVVe valve is designed to act as one-way valve, to help assist in propelling\nblood up the leg, and back to the heart and lungs. As a transcatheter\ndelivered device, the enVVe procedure will be performed under light sedation\nand should not require an over-night hospital stay.\n\nINVESTOR CONTACT:\n\nJTC Team, LLC\nJenene Thomas\nNVNO@jtcir.com\n(908) 824-0775\n\nSOURCE: enVVeno Medical Corporation\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/biotechnology/envveno-medical-to-participate-in-the-virtual-investor-closing-bell-series-1172665)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-06-02T13:01:00.588609171Z","server_sent_at_ms":1780405260588},"received_at":"2026-06-02T13:01:00.645Z","source_url":"https://www.accessnewswire.com/newsroom/en/biotechnology/envveno-medical-to-participate-in-the-virtual-investor-closing-bell-series-1172665"},"analysis":{"id":"41820","press_release_id":"52388","analysis_json":{"industry":{"label":"Medical Devices","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"enVVeno Medical announced that CEO Robert Berman will participate in a Virtual Investor Closing Bell webcast on June 9, 2026, at 4:00 PM ET.\n\nThe session will include a discussion of the company's recently reported FDA IDE approval for its enVVe System, a non-surgical replacement venous valve.\n\nA live video webcast and replay will be available on the company's website, followed by a live Q&A session with audience participants.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine IR event announcement; no new material data."},"keyFigures":{},"quotedText":"setting new standards of care for the treatment of deep venous disease","namedEntities":{"people":[{"name":"Robert Berman","role":"Chief Executive Officer"},{"name":"Jenene Thomas","role":"Investor Contact"}],"products":["enVVe System","enVVe valve"],"companies":[{"name":"enVVeno Medical Corporation","ticker":"NVNO"},{"name":"JTC Team, LLC","relationship":"investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor relations event announcement (webcast participation). No new operational, financial, or regulatory data disclosed; merely references previously reported IDE approval."},"tickerRelevance":{"others":[],"primary":"NVNO"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_ir_event","sectorWeight":"biotech_medtech","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"enVVeno Medical announced that CEO Robert Berman will participate in a Virtual Investor Closing Bell webcast on June 9, 2026, at 4:00 PM ET.\n\nThe session will include a discussion of the company's recently reported FDA IDE approval for its enVVe System, a non-surgical replacement venous valve.\n\nA live video webcast and replay will be available on the company's website, followed by a live Q&A session with audience participants.","key_figures":{},"named_entities":{"people":[{"name":"Robert Berman","role":"Chief Executive Officer"},{"name":"Jenene Thomas","role":"Investor Contact"}],"products":["enVVe System","enVVe valve"],"companies":[{"name":"enVVeno Medical Corporation","ticker":"NVNO"},{"name":"JTC Team, LLC","relationship":"investor relations firm"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-02T13:16:35.097Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_ir_event","sectorWeight":"biotech_medtech","issuerAuthored":true}},"durationMs":60784,"modelName":"george-droid-qwen-72b"}}